Chair: Norman Wolmark, USA
Introduction and the story so far: What makes a clinically useful assay?
Norman Wolmark, USA
Reviewing the evidence of clinical utility of genomic testing in patients with node-negative, ER+ breast cancer
Christy Russel, USA
A review of prospective trial and outcomes data evaluating the performance of genomic testing in patients with node-positive, ER+ breast cancer
Christian Jackisch, Germany
Multigene assays in breast cancer – do they all tell you the same thing?
Joseph Gligorov, France
Predicting late recurrence risk
Norman Wolmark, USA